UA92380C2 - Применение комбинации морфина и по меньшей мере одного опиатного антагониста для заместительной терапии опиатозависимых и героинозависимых лиц - Google Patents

Применение комбинации морфина и по меньшей мере одного опиатного антагониста для заместительной терапии опиатозависимых и героинозависимых лиц

Info

Publication number
UA92380C2
UA92380C2 UAA200810463A UAA200810463A UA92380C2 UA 92380 C2 UA92380 C2 UA 92380C2 UA A200810463 A UAA200810463 A UA A200810463A UA A200810463 A UAA200810463 A UA A200810463A UA 92380 C2 UA92380 C2 UA 92380C2
Authority
UA
Ukraine
Prior art keywords
opiate
oral
morphine
prevention
treatment
Prior art date
Application number
UAA200810463A
Other languages
English (en)
Ukrainian (uk)
Inventor
Ларс Херманн
Original Assignee
Фьёнукс Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36675685&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA92380(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Фьёнукс Аг filed Critical Фьёнукс Аг
Publication of UA92380C2 publication Critical patent/UA92380C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Addiction (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Изобретение касается применения нераздельной комбинации морфина или его физиологически приемлемых солей и по меньшей мере одного опиатного антагониста или его физиологически приемлемых солей с биодоступностью менее 5 % при пероральном введении для изготовления лекарственного средства, предназначенного только для перорального введения, для заместительной терапии опиатозависимых и героинозависимых лиц.
UAA200810463A 2006-01-19 2007-01-19 Применение комбинации морфина и по меньшей мере одного опиатного антагониста для заместительной терапии опиатозависимых и героинозависимых лиц UA92380C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06100578A EP1810678A1 (de) 2006-01-19 2006-01-19 Verwendung einer Kombination von Morphin und Naloxon zur Drogensubstitution

Publications (1)

Publication Number Publication Date
UA92380C2 true UA92380C2 (ru) 2010-10-25

Family

ID=36675685

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200810463A UA92380C2 (ru) 2006-01-19 2007-01-19 Применение комбинации морфина и по меньшей мере одного опиатного антагониста для заместительной терапии опиатозависимых и героинозависимых лиц

Country Status (19)

Country Link
US (2) US20100221339A1 (ru)
EP (2) EP1810678A1 (ru)
CN (2) CN101370503A (ru)
AT (1) ATE465735T1 (ru)
AU (1) AU2007206914B2 (ru)
CA (1) CA2637458C (ru)
CY (1) CY1110152T1 (ru)
DE (1) DE502007003589D1 (ru)
DK (1) DK1976524T4 (ru)
EA (1) EA014539B1 (ru)
ES (1) ES2345286T5 (ru)
HK (1) HK1198744A1 (ru)
HR (1) HRP20100373T4 (ru)
PL (1) PL1976524T5 (ru)
PT (1) PT1976524E (ru)
RS (1) RS51388B2 (ru)
SI (1) SI1976524T1 (ru)
UA (1) UA92380C2 (ru)
WO (1) WO2007082935A1 (ru)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102007024428A1 (de) 2007-05-25 2008-11-27 Hermann, Holger Lars, Dr. med. Verwendung von Naloxon als Abususschutz bei Nicht-Opioiden und Nicht-Opiaten
US20120040009A1 (en) 2009-04-22 2012-02-16 Lars Holger Hermann Particulate pharmaceutical composition with an opioid and an opioid antagonist
JP2012087101A (ja) 2010-10-21 2012-05-10 Holger Hermann Lars オピオイドおよびオピオイド拮抗薬を含む微粒子医薬組成物
WO2015089530A1 (de) 2013-12-20 2015-06-25 G.L. PHARMA GmbH Orale darreichungsform mit verzögerter freisetzung enthaltend morphin und naloxon
EP3082816B1 (en) 2013-12-20 2019-03-20 Indivior UK Limited Intranasal naloxone compositions and methods of making and using same
CN103695497B (zh) * 2013-12-20 2014-09-17 奇方(天津)医药科技有限公司 纳洛酮的酶法制备及其药物组合物
US20160256451A1 (en) * 2015-03-06 2016-09-08 Develco Pharma Schweiz Ag Dosage of naloxone
WO2016193456A2 (en) * 2015-06-03 2016-12-08 Develco Pharma Schweiz Ag Opioid receptor antagonist for use in treating patients with severe constipation

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1390772A (en) * 1971-05-07 1975-04-16 Endo Lab Oral narcotic composition
US4769372A (en) * 1986-06-18 1988-09-06 The Rockefeller University Method of treating patients suffering from chronic pain or chronic cough
US5478577A (en) * 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
US5580876A (en) † 1992-09-21 1996-12-03 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
SE9301057L (sv) 1993-03-30 1994-10-01 Pharmacia Ab Beredning med kontrollerad frisättning
DE4325465B4 (de) * 1993-07-29 2004-03-04 Zenz, Michael, Prof. Dr.med. Orales pharmazeutisches Präparat für die Schmerztherapie
AT403988B (de) 1994-05-18 1998-07-27 Lannacher Heilmittel Festes orales retardpräparat
US5965161A (en) 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
PT914097E (pt) * 1996-03-12 2002-06-28 Alza Corp Composicao e forma de dosagem compreendendo antagonista de opioide
DE59812355D1 (de) 1997-11-06 2005-01-13 Lannacher Heilmittel Orale Retard-Präparation enthaltend Tramadol sowie Verfahren zu ihrer Herstellung
DK1685839T3 (da) * 1997-12-22 2013-06-24 Euro Celtique Sa Farmaceutisk oral doseringsform omfattende en kombination af en opioidagonist og opioidantagonist
CN1204890C (zh) * 1997-12-22 2005-06-08 欧罗赛铁克股份有限公司 防止阿片样物质滥用的方法
WO1999040898A2 (en) 1998-02-12 1999-08-19 Centrapharm Inc. Sublingual drug formulations having combined rapid onset of action and long lasting therapeutic effect
AU776666B2 (en) * 2000-02-08 2004-09-16 Euro-Celtique S.A. Tamper-resistant oral opioid agonist formulations
CN1525851A (zh) † 2001-05-11 2004-09-01 ������ҩ�����޹�˾ 抗滥用阿片样物质控释剂型
US20030044458A1 (en) † 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
CA2478515C (en) 2002-04-05 2010-09-28 Purdue Pharma Pharmaceutical preparation containing oxycodone and naloxone
DK1551372T3 (en) 2002-09-20 2018-07-23 Alpharma Pharmaceuticals Llc SEQUERATION SUBSTANCES AND RELATED COMPOSITIONS AND PROCEDURES
US20050191244A1 (en) * 2002-10-25 2005-09-01 Gruenenthal Gmbh Abuse-resistant pharmaceutical dosage form
US20040110781A1 (en) * 2002-12-05 2004-06-10 Harmon Troy M. Pharmaceutical compositions containing indistinguishable drug components
AT503858B1 (de) 2003-06-05 2008-08-15 Lannacher Heilmittel Verfahren zur herstellung einer festen oralen pharmazeutischen zusammensetzung, enthaltend ein jodsalz
WO2006079550A2 (en) 2005-01-28 2006-08-03 Euro-Celtique S.A. Alcohol resistant dosage forms
EP1604666A1 (en) 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD)
FR2889810A1 (fr) * 2005-05-24 2007-02-23 Flamel Technologies Sa Forme medicamenteuse orale, microparticulaire, anti-mesurage
GB2438401A (en) 2006-05-25 2007-11-28 Alpharma Aps Preparation of morphinan derivatives comprising N-demethylation, reductive amination and O-demethylation steps
KR101486228B1 (ko) 2006-06-19 2015-01-26 알파마 파머슈티컬스 엘엘씨 약제학적 조성물

Also Published As

Publication number Publication date
WO2007082935A1 (de) 2007-07-26
EP1976524A1 (de) 2008-10-08
PL1976524T5 (pl) 2017-12-29
ES2345286T5 (es) 2017-04-25
CN101370503A (zh) 2009-02-18
RS51388B (sr) 2011-02-28
EP1810678A1 (de) 2007-07-25
DK1976524T4 (en) 2016-12-05
CY1110152T1 (el) 2015-01-14
HRP20100373T4 (hr) 2016-12-16
PT1976524E (pt) 2010-07-05
CA2637458C (en) 2015-03-10
US10507205B2 (en) 2019-12-17
AU2007206914B2 (en) 2012-08-23
SI1976524T1 (sl) 2010-08-31
DK1976524T3 (da) 2010-08-09
HK1198744A1 (en) 2015-06-05
HRP20100373T1 (en) 2010-08-31
ATE465735T1 (de) 2010-05-15
CA2637458A1 (en) 2007-07-26
US20100221339A1 (en) 2010-09-02
ES2345286T3 (es) 2010-09-20
DE502007003589D1 (de) 2010-06-10
PL1976524T3 (pl) 2010-10-29
RS51388B2 (sr) 2018-02-28
EP1976524B2 (de) 2016-08-10
EP1976524B1 (de) 2010-04-28
CN103893179A (zh) 2014-07-02
EA014539B1 (ru) 2010-12-30
EA200870182A1 (ru) 2009-02-27
AU2007206914A1 (en) 2007-07-26
US20170136005A1 (en) 2017-05-18

Similar Documents

Publication Publication Date Title
MY161079A (en) Tamper resistant oral pharmaceutical dosage forms comprising an opioid analgesic
WO2007087452A3 (en) Abuse resistant and extended release formulations and method of use thereof
HRP20100373T1 (en) Use of a combination of morphine and at least one opiate antagonist for treatment of opiate dependency and for prevention of non-oral opiate abuse in opiate addicts
EP2283843A3 (en) Opioids for the treatment of the chronic obstructive pulmonary disease (COPD)
UA109781C2 (uk) Сигма-ліганди для потенціювання аналгетичного ефекту опіоїдів і опіатів при післяопераційному болю і для послаблення залежності від них
IL179896A (en) Opioid with a delayed oral dosage form containing a mixture of opioid agonist and antagonist for use in the treatment of nervous leg syndrome
WO2007145863A3 (en) Sustained release formulation of naltrexone
WO2007133796A3 (en) Methods and compositions for treatment of sleep apnea comprising administration of an endothelin antagonist
IL175259A0 (en) Use of a deoxynojirimycin derivative or a pharmaceutically salt thereof
WO2009015734A3 (en) Dosage form comprising immediate release naproxen and sustained release opioid analgesic
Kumar et al. L-type calcium channel blockers, morphine and pain: Newer insights
WO2006053012A3 (en) Novel pharmaceutical compositions for treating acquired chronic pain and associated dysphoria
WO2004041154A3 (en) Abuse-resistant opioid dosage form
WO2005051489A3 (en) Fast dissolving solid oral dosage forms of galanthamine
MX2010010372A (es) Uso de la composicion morfina-metamizol como medicamento para el tratamiento del dolor neuropatico.
HK1145971A (en) Use of a combination of an opioid agonist and an opioid antagonist for the treatment of crohn's disease and the symptoms associated with crohn's disease
RU2005130810A (ru) Способ профилактики посттравматических инфекционных осложнений
SI1976524T2 (sl) Uporaba kombinacije morfija in vsaj enega opiatnega antagonista za zdravljenje odvisnosti od opiatov in za preprečevanje ne-peroralne zlorabe opiatov pri odvisnikih od opiatov
ATE545414T1 (de) Zubereitung zur verhinderung der alterungssymptome mit phytoöstrogenen und melatonin
AU2003240842A1 (en) Synergistic combination of an opioid analgesic and a nsaid